COVID-19
Conditions
Keywords
COVID-19, SARS-CoV-2, Photobiomodulation, Low level light therapy, PBM, Red light, Near-infrared light, At-home treatment, Remote
Brief summary
The objective of this study is to obtain data on the efficacy of the Vielight RX Plus in decreasing time to recovery of symptoms in subjects with COVID-19. The study will be conducted among COVID-19 positive subjects at home in self-isolation via electronic data collection (EDC). There will be no physical contact between the subjects and the Qualified Investigator (QI) or other study staff. This study aims to demonstrate that the Vielight RX Plus is a useful adjunct to standard of care (SOC). We hypothesize that the Vielight RX Plus will accelerate recovery and reduce viral infection severity.
Detailed description
This study is conducted entirely online. At no point will study staff be in direct contact with participants. The study will be managed by an independent clinical research organization (CRO), supporting a Qualified Investigator (QI). Vielight Inc will supply the RX Plus devices free of charge and will sponsor the study. Potential participants will be prompted to complete an online screening form if they are interested in participating. During the screening, the potential participant will be asked to upload a copy of their positive COVID-19 infection confirmation report and a valid ID. If the potential subject qualifies for the study, by statisfying all inclusion and exclusion criteria, the potential participant will then be prompted to complete an electronic informed consent form (ICF) via the electronic data collection (EDC) platform and will be enrolled into the study. This is a 30-day, prospective, randomized study, with no blinding. 280 participants will be randomized into two groups: Group 1: Standard of Care; Group 2: Standard of Care + Vielight RX Plus treatment. In Group 2, the Vielight RX Plus will be administered for 20 minutes twice a day, separated by at least 6 hours for the first 5 days. For the subsequent 25 days, treatment will be once per day. The Vielight RX Plus will be positioned over the upper most part of the breastbone to stimulate the thymus gland and within one nostril. During each of the 30-days, participants will be asked to complete a questionnaire to assess respiratory symptom severity, and log a daily dairy as well as oxygen saturation level (using a portable oximeter). The primary measure is time to overall recovery in days.
Interventions
DEVICEVielight RX Plus
The Vielight RX Plus is designed to deliver near-infrared light and red light via LEDs placed directly on the manubrium of the sternum (which covers the thymus gland) and inside one nostril, respectively.
Sponsors
Vielight Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Prospective, randomized trial
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Confirmation of COVID-19 infection * Experiencing moderate to severe respiratory symptoms * Between 18-65 years of age
Exclusion criteria
* Need for hospitalization at the time of diagnosis * Current need for supplemental oxygen or positive pressure support and/or has required supplemental oxygen or positive pressure support for \>or= 24 hours * \>10 days since symptom onset * Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) * Pregnant * Positive for Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) or Human Immunodeficiency Virus * Inability to electronically complete study questionnaires in English
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to recovery | 30 days |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization rate | 30 days |
| Time to elimination of COVID-19 related symptoms | 30 days |
| Mean number of days with mild COVID-19 related symptoms | 30 days |
| Mean number of days with mild overall respiratory symptoms | 30 days |
| Mortality | 30 days |
| Time to elimination of symptoms | 30 days |
| Average number of days with mild respiratory symptoms | 30 days |
| Oxygen saturation | 30 days |
| Time to symptom reduction | 30 days |
Countries
Canada, United States
Outcome results
None listed